Integer (NYSE:ITGR) Updates FY 2025 Earnings Guidance

Integer (NYSE:ITGR) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.840-6.200 for the period, compared to the consensus EPS estimate of 6.070. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Integer Price Performance

ITGR traded down $3.76 during trading on Friday, reaching $131.46. 226,062 shares of the company were exchanged, compared to its average volume of 241,928. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.41 billion, a price-to-earnings ratio of 40.62, a P/E/G ratio of 1.82 and a beta of 1.13. Integer has a 12-month low of $98.63 and a 12-month high of $146.36. The company’s 50-day moving average is $137.92 and its two-hundred day moving average is $132.31.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. Research analysts forecast that Integer will post 5.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ITGR. KeyCorp increased their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Truist Financial raised their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $140.00 price objective (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday. Finally, Citigroup boosted their price target on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $147.67.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.